2459 related articles for article (PubMed ID: 20628086)
1. Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.
Bailey SD; Xie C; Do R; Montpetit A; Diaz R; Mohan V; Keavney B; Yusuf S; Gerstein HC; Engert JC; Anand S;
Diabetes Care; 2010 Oct; 33(10):2250-3. PubMed ID: 20628086
[TBL] [Abstract][Full Text] [Related]
2. [DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular desease].
Scheen AJ
Rev Med Liege; 2006 Oct; 61(10):728-32. PubMed ID: 17209507
[TBL] [Abstract][Full Text] [Related]
3. [Influence of diabetes incidence by ramipril and rosiglitazone: DREAM study (diabetes reduction assessment with ramipril and rosiglitazone medication)].
Standl E; Nitschmann S
Internist (Berl); 2007 Oct; 48(10):1173-6. PubMed ID: 17846732
[No Abstract] [Full Text] [Related]
4. Incidence of diabetes following ramipril or rosiglitazone withdrawal.
DREAM Trial Investigators
Diabetes Care; 2011 Jun; 34(6):1265-9. PubMed ID: 21515846
[TBL] [Abstract][Full Text] [Related]
5. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.
; Dagenais GR; Gerstein HC; Holman R; Budaj A; Escalante A; Hedner T; Keltai M; Lonn E; McFarlane S; McQueen M; Teo K; Sheridan P; Bosch J; Pogue J; Yusuf S
Diabetes Care; 2008 May; 31(5):1007-14. PubMed ID: 18268075
[TBL] [Abstract][Full Text] [Related]
6. Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial.
Hanley AJ; Zinman B; Sheridan P; Yusuf S; Gerstein HC;
Diabetes Care; 2010 Mar; 33(3):608-13. PubMed ID: 20009095
[TBL] [Abstract][Full Text] [Related]
7. Diabetes prevention between RAAS inhibition and PPAR-gamma stimulation: the diabetes reduction assessment with ramipril and rosiglitazone medication (DREAM) trial.
McFarlane SI; Provilus A; Shin JJ
J Cardiometab Syndr; 2007; 2(2):149-50. PubMed ID: 17684471
[No Abstract] [Full Text] [Related]
8. Effect of rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed, untreated diabetes and IGT patients: 1-year randomised, double-blind, placebo-controlled study.
Rahman S; Ismail AA; Ismail SB; Naing NN; Abdul Rahman AR
Eur J Clin Pharmacol; 2007 Aug; 63(8):733-41. PubMed ID: 17565489
[TBL] [Abstract][Full Text] [Related]
9. Thiazolidinedione-induced edema in patients with heart failure.
Stroup JS
Am J Health Syst Pharm; 2007 Dec; 64(23):2426-30; author reply 2430. PubMed ID: 18029947
[No Abstract] [Full Text] [Related]
10. Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes.
; Gerstein HC; Mohan V; Avezum A; Bergenstal RM; Chiasson JL; Garrido M; MacKinnon I; Rao PV; Zinman B; Jung H; Joldersma L; Bosch J; Yusuf S
Diabetologia; 2011 Mar; 54(3):487-95. PubMed ID: 21116607
[TBL] [Abstract][Full Text] [Related]
11. Effects of ethnicity on diabetes incidence and prevention: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.
Boyko EJ; Gerstein HC; Mohan V; Yusuf S; Sheridan P; Anand S; Shaw JE;
Diabet Med; 2010 Nov; 27(11):1226-32. PubMed ID: 20950379
[TBL] [Abstract][Full Text] [Related]
12. Trials that matter: rosiglitazone, ramipril, and the prevention of type 2 diabetes.
Nathan DM; Berkwits M
Ann Intern Med; 2007 Mar; 146(6):461-3. PubMed ID: 17371892
[No Abstract] [Full Text] [Related]
13. DREAM and ADOPT: rosiglitazone does what it says on the packet.
Bilous R
Diabet Med; 2007 Feb; 24(2):107-9. PubMed ID: 17257270
[No Abstract] [Full Text] [Related]
14. [Three studies in type 2 diabetes: DREAM the wash-out results].
Roussel R
Ann Endocrinol (Paris); 2007 Jun; 68 Suppl 1():36-8. PubMed ID: 17961660
[No Abstract] [Full Text] [Related]
15. Genetic predisposition and nongenetic risk factors of thiazolidinedione-related edema in patients with type 2 diabetes.
Chang TJ; Liu PH; Liang YC; Chang YC; Jiang YD; Li HY; Lo MT; Chen HS; Chuang LM
Pharmacogenet Genomics; 2011 Dec; 21(12):829-36. PubMed ID: 21934636
[TBL] [Abstract][Full Text] [Related]
16. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications.
Mudaliar S; Chang AR; Henry RR
Endocr Pract; 2003; 9(5):406-16. PubMed ID: 14583425
[TBL] [Abstract][Full Text] [Related]
17. Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone).
Lonn EM; Gerstein HC; Sheridan P; Smith S; Diaz R; Mohan V; Bosch J; Yusuf S; Dagenais GR;
J Am Coll Cardiol; 2009 Jun; 53(22):2028-35. PubMed ID: 19477351
[TBL] [Abstract][Full Text] [Related]
18. Diabetes prevention: still no effective drugs.
Prescrire Int; 2007 Dec; 16(92):258. PubMed ID: 18095391
[TBL] [Abstract][Full Text] [Related]
19. [Heart failure with thiazolidinedione treatment: what do we know today?].
Erdmann E
Dtsch Med Wochenschr; 2009 Jan; 134(4):154-8. PubMed ID: 19148858
[TBL] [Abstract][Full Text] [Related]
20. Unilateral edema due to a thiazolidinedione.
Bell DS
Diabetes Care; 2003 Sep; 26(9):2700. PubMed ID: 12941750
[No Abstract] [Full Text] [Related]
[Next] [New Search]
